Does nemolizumab significantly affect warfarin exposure in patients with moderate-to-severe atopic dermatitis?

Nemolizumab did not cause clinically significant changes in warfarin exposure in a study of 14 subjects with moderate-to-severe atopic dermatitis receiving 60 mg initially followed by 30 mg every four weeks for 12 weeks.